News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • Vistra positioned as a direct beneficiary of surging AI data-center power demand.
  • Shares have retraced from a 52-week high, creating a buy-the-dip entry near $141.50.
  • Analyst trade setup targets $170 with a $128 stop for a mid-term play.
  • Upside depends on securing long-term hyperscaler contracts and infrastructure joint ventures.
  • Execution and regulatory risks could invalidate the investment thesis.
  • AI-driven power scarcity may boost valuations across wholesale generators.

Latest Articles

Vivos Therapeutics Announces Issuance of New US Patent Broadening Protection for Its Vivos CARE Oral Medical Device Technology

Vivos Therapeutics Announces Issuance of New US Patent Broadening Protection for Its Vivos CARE Oral Medical Device Technology

Vivos Therapeutics announced the issuance of a new US patent (No. 12,697,190) that broadens protection for its Vivos CARE oral medical devices, designed to treat obstructive sleep apnea (OSA). This continuation patent complements their earlier patent, enhancing protection against competitors. With FDA 510(k) clearances for treating severe OSA in ad…

Splash Beverage Group Partners with Veteran Cannabinoid Drug-Development Team to Advance CannEpil® Through FDA Veterinary Pathway

Splash Beverage Group Partners with Veteran Cannabinoid Drug-Development Team to Advance CannEpil® Through FDA Veterinary Pathway

Splash Beverage Group has entered a strategic collaboration with Lupvindol Biosciences Ltd. to advance CannEpil® as a potential FDA-regulated veterinary pharmaceutical product focused initially on companion-animal oncology and chronic pain management. The program aims to navigate the FDA veterinary drug approval pathway to achieve conditional appro…

Acrivon Advances ACR-2316, a Potential First-in-Class WEE1/PKMYT1 Inhibitor, into Randomized Dose Expansion in its Ongoing Phase 1/2 Study

Acrivon Advances ACR-2316, a Potential First-in-Class WEE1/PKMYT1 Inhibitor, into Randomized Dose Expansion in its Ongoing Phase 1/2 Study

Acrivon Therapeutics announced that its investigational drug ACR-2316, a novel WEE1/PKMYT1 inhibitor, has progressed into the randomized dose expansion phase of its ongoing Phase 1/2 clinical trial. The advancement follows a favorable safety profile and evidence of durable clinical activity, including tumor shrinkage and partial responses in heavil…

Charlton Aria Acquisition Corporation Announces Extension of the Deadline for an Initial Business Combination

Charlton Aria Acquisition Corporation Announces Extension of the Deadline for an Initial Business Combination

Charlton Aria Acquisition Corporation, a Cayman Islands exempted blank check company listed on Nasdaq, announced a three-month extension until October 25, 2026, for completing its initial business combination. This marks the second extension after the Sponsor deposited $850,000 into the trust account, allowing more time to identify and consummate a…

FingerMotion Announces Leadership Change

FingerMotion Announces Leadership Change

FingerMotion, Inc., a Nasdaq-listed mobile services and technology company, announced a leadership change with the appointment of Jolie Kahn as CEO, succeeding Martin Shen. Kahn brings extensive experience in corporate finance, public company management, and digital asset-related businesses. The company aims to leverage its growing user base and in…

XFLT Urges Shareholders to Approve the King Street Sub-Adviser and Effect Liquidity Plan Ahead of August 6th Meeting

XFLT Urges Shareholders to Approve the King Street Sub-Adviser and Effect Liquidity Plan Ahead of August 6th Meeting

XAI Floating Rate & Alternative Income Trust (XFLT) is urging shareholders to vote in favor of appointing King Street Capital Management's subsidiary as long-term sub-adviser and approve a liquidity plan involving tender offers to repurchase 25% of fund shares. Key proxy advisory firms and investment research services recommend voting for the propo…

TSX Futures Rise as Iran Peace Prospects and Shopify Forecast Lift Sentiment

TSX Futures Rise as Iran Peace Prospects and Shopify Forecast Lift Sentiment

Futures tied to Canada’s primary stock benchmark were trading higher as market participants reacted to signs of progress toward a potential US-Iran agreement and parsed quarterly results and guidance from Shopify. The S&P/TSX 60 futures climbed materially, aided by strength in technology and metal mining names. Simultaneously, developments in oil a…

SciSparc: Subsidiary NeuroThera Labs Launches Phase IIb Clinical Trial at Yale Child Study Center for First-of-its-kind Treatment for Tourette Syndrome

SciSparc: Subsidiary NeuroThera Labs Launches Phase IIb Clinical Trial at Yale Child Study Center for First-of-its-kind Treatment for Tourette Syndrome

SciSparc Ltd., through its subsidiary NeuroThera Labs, has launched a Phase IIb clinical trial of SCI-110, a cannabinoid-based drug candidate for Tourette Syndrome treatment, at Yale Child Study Center in the USA. This multinational trial also includes sites in Germany and Israel and builds on positive Phase IIa results, aiming to advance regulator…

Ocean Power Technologies Selected for Participation in $40 Million U.S. Navy Project for Autonomous Ocean Mapping

Ocean Power Technologies Selected for Participation in $40 Million U.S. Navy Project for Autonomous Ocean Mapping

Ocean Power Technologies, Inc. (NYSE American: OPTT) has been chosen as one of six potential awardees for a $40 million multiple-award contract by the U.S. Naval Oceanographic Office to provide high-resolution ocean-floor mapping using long-endurance unmanned surface vehicles. The contract spans two years with task orders competed among awardees an…